RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study Nov 11, 2016
DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences Nov 8, 2016
RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA® and Expected Timing of Top-Line Results Nov 4, 2016
DelMar Pharmaceuticals Presents Overview of VAL-083’s Unique Anticancer Mechanism at the European Association of Neuro-Oncology (EANO) Annual Meeting Oct 18, 2016
Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease Oct 5, 2016
DelMar Pharmaceuticals Presents Data Supporting the Potential of VAL-083 as a New Treatment for Ovarian Cancer at the 11th Biennial Ovarian Cancer Research Symposium Sep 14, 2016
DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer Sep 8, 2016
DelMar Pharmaceuticals to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016 Aug 31, 2016
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy Aug 30, 2016
DelMar Pharmaceuticals to Present at the 11th Biennial Ovarian Cancer Research Symposium Aug 12, 2016
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208) Aug 12, 2016
RedHill Biopharma Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis Aug 2, 2016
